



Attorney's Docket No.: 009848-0276371

TECH CENTER 1600/2900

AUG 27 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : KUFER, et al.

Art Unit : 1642

Serial No. : 09/744,625

Examiner : Yu, M. Ph.D.

Filed : July 16, 2001

Title : HETEROMINIBODIES

Assistant Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-14501

RESPONSE TO OFFICE COMMUNICATION

In response to the Detailed Action mailed May 20, 2003, in connection with the above-identified application, the time to reply having been extended to August 20, 2003, by petition and fee under 37 C.F.R. §1.136(a), Applicants hereby elect the product having the following molecular structure, readable upon by Claims 1, 2, 5, 6, 7, 8, 9, 11, 19, 20, 21, 22, 33, 34, 35, 40:

HD70 V_L – 14 to 25 amino acid linker - HD70 V_H - arbitrary Ig hinge region – C_k or C_{H1}

08/25/2003 MAHMED1 00000050 502212 09744625 B7 – arbitrary Ig hinge region – C_k or C_{H1}

01 FC:2252 205.00 DA

Support for the multifunctional compound having the molecular structure shown above, with an antigen-binding region specific for a tumor antigen and a T-cell costimulatory ligand region, is found throughout the specification, in particular on page 11 at lines 14-8. Support for an antigen-binding region comprising HD70 V_L, and HD70 V_H regions of the HD70 human anti-human EpCAM antibody is found on page 12 at lines 14-15, and on page 16, lines 3-5. Support for the T-cell costimulatory ligand region is found throughout the specification, in particular on page 11 at lines 19-31, and support for a T-cell costimulatory ligand region comprising members of the B7 family of proteins is found on page 11 at line 31 and page 12 at lines 23-25. Support for multifunctional compounds wherein polypeptides with receptor or ligand function are fused

to C_L(of which C_K is one type) or C_{H1} via Ig hinge regions is found throughout the specification, in particular on page 11 at lines 6-10 and on page 15 at lines 16-26. Support for choice of constant domains C_K or C_{H1} is found throughout the specification, in particular on page 6 lines 16-22 and page 15 at lines 12-14.


CONCLUSION

Claims 1 to 27, 33, 34, 35, 40, and 41 have been elected and are currently pending in the present application, and a request for rejoinder of Group III, claims 36 to 39, is currently pending. The molecular structure disclosed above has been elected for further examination.

A petition and fee under 37 C.F.R. §1.136(a) for extension of time to reply is submitted herewith. Please charge any additional fees, or make any credits, to Deposit Account No. 50-2212.

Respectfully submitted,

Date: August 22, 2003


Donna O. Perdue, Ph.D.
Reg. No. 51,166

Pillsbury Winthrop LLP
11682 El Camino Real, Suite 200
San Diego, CA 92130-2593
Telephone: (858) 509-4093
Facsimile: (858) 509-4010